Radiolabeled TSPO Targeted Molecular Probe in Glioma

Clinical Application of a Novel Radiolabeled Translocator Protein (TSPO) Targeted Small Molecular Probe in Neuroinflammation Imaging of Glioma

Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium [68Ga]-DOTA-HK-011 in inflammation imaging of glioma.

Inclusion Criteria:

• Voluntary subjects, patients, or their legal representatives must sign the informed consent form.
• There are no restrictions on the gender of volunteers; age must be between 18 and 75 years, inclusive.
• Other imaging examination methods (e.g., CT, MRI) show the presence of intracranial lesions.
• Patients with brain glioma who are scheduled for surgery or biopsy that will provide final pathological results.
• Patients must have a kidney GFR > 50 mL/min, ERPF > 280 mL/min, platelet count (PLT) > 75,000/μL, white blood cell count (WBC) > 3,000/μL, and alanine aminotransferase (ALT) and asparta.

Exclusion Criteria:

• Individuals with a history of allergy to drugs with similar chemical or biological components to TSPO, a history of atopy, or currently suffering from allergic diseases.
• Individuals currently participating in other drug clinical studies, or who have previously participated in any drug (excluding vitamins and minerals) clinical studies.
• Individuals with other difficult-to-control clinical conditions, such as HIV infection, hepatitis C virus infection, active hepatitis B, other severe chronic infections, or serious mental, neurological, cardiovascular, respiratory, or other systemic diseases.
• Red blood cell count (RBC) < 4×10^12/L, white blood cell count (WBC) < 3×10^9/L, hemoglobin < 110 g/L, platelet count (PLT) < 75×10^9/L.
• Significant liver and kidney function abnormalities, glomerular filtration rate (GFR) < 50 ml/min.
• Tumor burden involving more than 50% of the affected organ, or significant spinal cord compression.
• Expected survival time less than six months, or having received chemotherapy within the past six months.
• Individuals with severe acute comorbidities or severe refractory mental disorders.
• Pregnant or breastfeeding women (pregnancy defined as a positive urine pregnancy test).
• Individuals whose physical condition is unsuitable for radioactive examination.
• Other circumstances deemed unsuitable for participation in the trial by the investigator.